IR

• 24 Mar, 2026
  Spago Nanomedicals abstract om Tumorad® accepterat för presentation på radiofarma-konferens
• 24 Mar, 2026
  Spago Nanomedical’s abstract on Tumorad® accepted for presentation at radiopharma conference
• 17 Mar, 2026
  Spago Nanomedical fortsätter rekryteringen i fas I/IIa-studien Tumorad-01 efter positiv DMC-rekommendation
• 17 Mar, 2026
  Spago Nanomedical continues recruitment in the phase I/IIa Tumorad-01 study following positive DMC recommendation
• 10 Mar, 2026
  Spago Nanomedical strengthens CMC and supply capabilities to support next phase of Tumorad development
• 10 Mar, 2026
  Spago Nanomedical stärker resurserna inom CMC och tillverkning inför nästa fas i utvecklingen av Tumorad
• 5 Feb, 2026
  Spago Nanomedical bokslutskommuniké januari-december 2025
• 5 Feb, 2026
  Spago Nanomedical year-end report January-December, 2025
• 8 Dec, 2025
  Valberedning utsedd inför Spago Nanomedicals årsstämma 2026
• 8 Dec, 2025
  Nomination committee appointed for Spago Nanomedical’s Annual General Meeting 2026